SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-029314
Filing Date
2024-03-11
Accepted
2024-03-11 16:26:19
Documents
49
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20240131.htm   iXBRL 10-Q 1315456
2 EX-4.1 kalv-ex4_1.htm EX-4.1 118588
3 EX-31.1 kalv-ex31_1.htm EX-31.1 14910
4 EX-32.1 kalv-ex32_1.htm EX-32.1 7516
  Complete submission text file 0000950170-24-029314.txt   4776488

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20240131.xsd EX-101.SCH 610655
50 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20240131_htm.xml XML 690353
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 24738398
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)